In this video, I’m breaking down the most exciting
drug in metabolic medicine right now —retatrutide,
Eli Lilly’s investigational triple agonist that just
reported Phase 3 results that stopped me in my tracks.
As a double board-certified endocrinologist, I’ve
been following this drug closely — and the TRIUMPH-1 and TRANSCEND data are unlike anything I’ve seen in this class.
📊 WHAT THE DATA SHOWS:
▸ 70 lbs lost (28.3% body weight) at 80 weeks on
the highest dose
▸ Up to 30% weight loss at 2 years in severe obesity
▸ 65% of patients dropped below a BMI of 30
▸ A1c reductions of up to 2.0% in Type 2 diabetes
▸ 46% of diabetic patients achieved a completely
normal A1c
💊 WHAT MAKES RETATRUTIDE DIFFERENT:
Semaglutide (Ozempic, Wegovy) activates 1 receptor.
Tirzepatide (Mounjaro, Zepbound) activates 2.
Retatrutide activates 3 — GLP-1, GIP, AND glucagon —
making it the most potent agent ever studied in this class.
⚠️ IMPORTANT: Retatrutide is not yet FDA approved.
A regulatory submission is anticipated in 2026.
This video is for educational purposes only and does
not constitute medical advice.
─────────────────────────────────────────
🔔 SUBSCRIBE for weekly science-backed updates on
hormones, metabolism, GLP-1 medications, and
perimenopause health from a practicing endocrinologist.
─────────────────────────────────────────
─────────────────────────────────────────
👩⚕️ ABOUT DR. ALESSIA ROEHNELT
Double board-certified in Endocrinology and Internal
Medicine. Practicing at EndoHealth MD in Westfield, NJ
with telehealth across NJ, NY, and FL.
📍 endohealthmedical.com
📱 Instagram & TikTok: @endohealthdoc
─────────────────────────────────────────
CHAPTERS:
0:00 Hook — The drug changing everything
0:15 What is retatrutide?
0:30 How it differs from semaglutide & tirzepatide
1:00 TRIUMPH-1 Phase 3 weight loss results
1:45 TRANSCEND — A1c and diabetes data
2:30 Who this drug may be for
3:00 When to expect FDA approval
─────────────────────────────────────────
DISCLAIMER: This video is intended for educational
purposes only and does not constitute medical advice.
Always consult a licensed healthcare provider before
starting, stopping, or adjusting any medication.
#retatrutide #GLP1 #weightloss #Ozempic #tirzepatide
#semaglutide #Mounjaro #Wegovy #metabolichealth
#endocrinology #obesity #type2diabetes #hormonehealth
#perimenopause #insulinresistance #endohealthdoc